<p>Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events</p>

英夫利昔单抗 医学 银屑病 生物仿制药 不利影响 甲氨蝶呤 肿瘤坏死因子α 免疫学 皮肤病科 内科学
作者
Smriti Subedi,Yu Gong,Youdong Chen,Yuling Shi
出处
期刊:Drug Design Development and Therapy [Dove Medical Press]
卷期号:Volume 13: 2491-2502 被引量:57
标识
DOI:10.2147/dddt.s200147
摘要

Psoriasis is a chronic immune-mediated skin disease affecting multiple systems, and tumor necrosis factor-α (TNF-α) plays a significant role in the initiation and progression of the disease process. Psoriasis has a high prevalence rate in the Western world, especially in the USA and Australia; in China, although the prevalence rate is much lower, there is still a large number of patients suffering from psoriasis and its comorbidities. As TNF-α is thought to be crucial in the pathogenesis of psoriasis, specific therapy blocking TNF-α may be beneficial in the treatment of this disease. Infliximab, a murine-human monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis, with better skin clearance and faster onset of action than topical medications such as methotrexate, narrow-band ultraviolet B, and calcipotriol. Lack of adherence to infliximab therapy is mainly due to loss of response (LOR) over time and adverse events, particularly because infusion reactions are usually encountered. Anti-infliximab antibody is thought to be responsible for the LOR and infusion reactions. However, the mechanism underlying the formation of anti-infliximab antibody and its side effects remains unclear. Further studies identifying patients at risk for LOR will probably help clinicians to select the right patients for anti-TNF-α therapy and to increase the durability of the treatment. This review discusses the efficacy of infliximab as demonstrated by various clinical trials, LOR to infliximab, combatting LOR, as well as the adverse events usually faced during the use of infliximab therapy and the infliximab biosimilar Remsima®. We hope that we can discover a better way to use infliximab in the therapy of psoriasis from the current research data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈昊完成签到,获得积分10
7秒前
8秒前
tian发布了新的文献求助10
10秒前
13秒前
13秒前
龙舞星完成签到,获得积分10
14秒前
15秒前
王涉发布了新的文献求助10
17秒前
普鲁卡因发布了新的文献求助10
18秒前
量子星尘发布了新的文献求助10
20秒前
柚子完成签到,获得积分10
24秒前
25秒前
马儿饿了要吃草完成签到,获得积分10
25秒前
27秒前
sudor123456完成签到,获得积分10
32秒前
NXK发布了新的文献求助10
32秒前
打打应助普鲁卡因采纳,获得10
35秒前
37秒前
lii完成签到,获得积分10
37秒前
jiaolulu发布了新的文献求助10
43秒前
个性惜蕊完成签到,获得积分10
43秒前
46秒前
轩辕书白完成签到,获得积分10
47秒前
qinzhikai完成签到,获得积分10
51秒前
天真的冬瓜完成签到,获得积分10
52秒前
小溜溜完成签到 ,获得积分10
53秒前
普鲁卡因发布了新的文献求助10
54秒前
tian发布了新的文献求助10
55秒前
桃花源的瓶起子完成签到 ,获得积分10
59秒前
平凡世界完成签到 ,获得积分10
1分钟前
YYLLTX完成签到,获得积分10
1分钟前
畅快山兰完成签到 ,获得积分10
1分钟前
gaoxiaogao完成签到,获得积分10
1分钟前
舒适怀寒完成签到 ,获得积分10
1分钟前
shenglll完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
普鲁卡因发布了新的文献求助10
1分钟前
Liang完成签到,获得积分10
1分钟前
爱思考的小笨笨完成签到,获得积分10
1分钟前
123456完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022